WO2022102457A1 - Comprimé à désintégration orale contenant de la linagliptine - Google Patents

Comprimé à désintégration orale contenant de la linagliptine Download PDF

Info

Publication number
WO2022102457A1
WO2022102457A1 PCT/JP2021/040258 JP2021040258W WO2022102457A1 WO 2022102457 A1 WO2022102457 A1 WO 2022102457A1 JP 2021040258 W JP2021040258 W JP 2021040258W WO 2022102457 A1 WO2022102457 A1 WO 2022102457A1
Authority
WO
WIPO (PCT)
Prior art keywords
linagliptin
orally disintegrating
disintegrating tablet
carmellose
tablet
Prior art date
Application number
PCT/JP2021/040258
Other languages
English (en)
Japanese (ja)
Inventor
康史 福原
克彦 尾曲
Original Assignee
沢井製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 沢井製薬株式会社 filed Critical 沢井製薬株式会社
Priority to JP2022561834A priority Critical patent/JPWO2022102457A1/ja
Publication of WO2022102457A1 publication Critical patent/WO2022102457A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne : un comprimé à désintégration orale contenant de la linagliptine qui est capable de masquer suffisamment l'amertume ; et un procédé de production de celui-ci. Selon un mode de réalisation, la présente invention concerne un comprimé à désintégration orale contenant de la linagliptine contenant : de la linagliptine; et un additif comprenant au moins un élément choisi dans le groupe constitué par la carmellose calcique, la croscarmellose sodique, la carmellose et l'acide glycolique d'amidon sodique. L'additif peut également comprendre au moins un élément choisi dans le groupe constitué par la carmellose calcique, le sodium réticulé et la carmellose.
PCT/JP2021/040258 2020-11-10 2021-11-01 Comprimé à désintégration orale contenant de la linagliptine WO2022102457A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022561834A JPWO2022102457A1 (fr) 2020-11-10 2021-11-01

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-187106 2020-11-10
JP2020187106 2020-11-10

Publications (1)

Publication Number Publication Date
WO2022102457A1 true WO2022102457A1 (fr) 2022-05-19

Family

ID=81602200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/040258 WO2022102457A1 (fr) 2020-11-10 2021-11-01 Comprimé à désintégration orale contenant de la linagliptine

Country Status (2)

Country Link
JP (1) JPWO2022102457A1 (fr)
WO (1) WO2022102457A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022192036A (ja) * 2021-06-16 2022-12-28 日本ジェネリック株式会社 リナグリプチン含有製剤及びリナグリプチン含有口腔内崩壊性錠剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013161823A1 (fr) * 2012-04-24 2013-10-31 第一三共株式会社 Comprimé à désintégration orale et son procédé de production
EP2848242A1 (fr) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations orodispersibles de Linagliptin
CN105853382A (zh) * 2016-05-19 2016-08-17 广州迈达康医药科技有限公司 一种利格列汀口崩片及其制备方法
JP2018530566A (ja) * 2015-10-09 2018-10-18 ヘクサル・アクチェンゲゼルシャフトＨｅｘａｌ ＡＧ ８−［（３ｒ）−３−アミノ−１−ピペリジニル］−７−（２−ブチン−１−イル）−３，７−ジヒドロ−３−メチル−１−［４−メチル−２−キナゾリニル）メチル］−１ｈ−プリン−２，６−ジオンまたは薬学上許容できるその塩を含有する医薬組成物
JP2020158435A (ja) * 2019-03-26 2020-10-01 エルメッド株式会社 リナグリプチン含有医薬組成物及びその製造方法、並びにリナグリプチン含有医薬組成物の品質の向上方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013161823A1 (fr) * 2012-04-24 2013-10-31 第一三共株式会社 Comprimé à désintégration orale et son procédé de production
EP2848242A1 (fr) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations orodispersibles de Linagliptin
JP2018530566A (ja) * 2015-10-09 2018-10-18 ヘクサル・アクチェンゲゼルシャフトＨｅｘａｌ ＡＧ ８−［（３ｒ）−３−アミノ−１−ピペリジニル］−７−（２−ブチン−１−イル）−３，７−ジヒドロ−３−メチル−１−［４−メチル−２−キナゾリニル）メチル］−１ｈ−プリン−２，６−ジオンまたは薬学上許容できるその塩を含有する医薬組成物
CN105853382A (zh) * 2016-05-19 2016-08-17 广州迈达康医药科技有限公司 一种利格列汀口崩片及其制备方法
JP2020158435A (ja) * 2019-03-26 2020-10-01 エルメッド株式会社 リナグリプチン含有医薬組成物及びその製造方法、並びにリナグリプチン含有医薬組成物の品質の向上方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAKAGAWA, TOMOYA ET AL.: "Drug Development Research with Taste Sensor, Part 2: Taste Masking and Formulation Development of Donepezil Hydrochloride OD Tablets", PHARM TECH JAPAN, vol. 28, no. 3, 1 January 2012 (2012-01-01), JP , pages 511 - 517, XP009536655, ISSN: 0910-4739 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022192036A (ja) * 2021-06-16 2022-12-28 日本ジェネリック株式会社 リナグリプチン含有製剤及びリナグリプチン含有口腔内崩壊性錠剤
JP7210794B2 (ja) 2021-06-16 2023-01-23 日本ジェネリック株式会社 リナグリプチン含有製剤及びリナグリプチン含有口腔内崩壊性錠剤

Also Published As

Publication number Publication date
JPWO2022102457A1 (fr) 2022-05-19

Similar Documents

Publication Publication Date Title
KR101612137B1 (ko) 구강 내 붕괴정
KR101465803B1 (ko) 구강내 붕괴 정제
KR101554374B1 (ko) 구강 붕해정
JP4551092B2 (ja) 口腔内速崩壊性錠剤
JP5296456B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2009521523A (ja) 口中溶解性医薬組成物およびその製造方法
US20150320688A1 (en) Tablet quickly disintegrating in the oral cavity and method for producing the same
JP2001058944A (ja) 速崩壊性固形製剤
KR101203186B1 (ko) 약물의 맛이 차폐된 경구용 약학 조성물 및 그 제조 방법
JP2006070046A (ja) 速崩壊性固形製剤
KR20190089892A (ko) 디아민 유도체를 함유하는 구강내 붕괴정
JP5630902B2 (ja) ゾルピデム酒石酸塩含有口腔内崩壊錠の製造方法
JP2017141299A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP4358117B2 (ja) 口腔内速崩壊錠
JP6803250B2 (ja) エレトリプタン臭化水素酸塩含有口腔内崩壊錠
KR20150002453A (ko) 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
WO2022102457A1 (fr) Comprimé à désintégration orale contenant de la linagliptine
JPWO2009054432A1 (ja) 口腔内速崩壊性医薬組成物およびその製造方法
JP5062872B2 (ja) 不快な味を低減した口腔内崩壊錠剤
JP5978335B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6151413B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP5714652B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2010053048A (ja) 苦味が緩和されたイルベサルタン含有医薬組成物
WO2015087823A1 (fr) Composition contenant du carbonate pour comprimé orodispersible, et comprimé orodispersible
JP2000273038A (ja) 口腔内溶解性錠剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21891704

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022561834

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21891704

Country of ref document: EP

Kind code of ref document: A1